Enjoy complimentary customisation on priority with our Enterprise License!
Acute coronary syndrome (ACS) impacts the functioning of the heart due to the insufficient supply of blood in the coronary arteries. Atherosclerosis, a buildup of plaque in the coronary arteries, is a major cause of ACS. ACS is consequent in high mortality rates among younger people and in and low and middle-income countries. ACS includes ST-elevation myocardial infarction (STEMI), non-STEMI, and unstable angina. This disease also results in mortality and disability in APAC. Technavio’s market research analysts have predicted that with the introduction of the 12-lead electrocardiogram, as one of the most common diagnostic approaches to treat coronary syndromes, acute coronary syndrome market worth will increase in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are in the Phase III development stage and a considerable number of molecules are being evolved for better results.
According to the acute coronary syndrome market forecast, this pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for acute coronary syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report
The intravitreal route of administration (ROA) involves the application of the drug directly onto the vitreous fluid and in the subretinal technique, the molecules are applied to the subretinal space, which will have a more direct effect on the target cells.
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for acute coronary syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development for monotherapy.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.